Logo image of EAPI.PA

EUROAPI SASU (EAPI.PA) Stock Fundamental Analysis

EPA:EAPI - FR0014008VX5 - Common Stock

2.88 EUR
-0.04 (-1.5%)
Last: 9/10/2025, 5:28:17 PM
Fundamental Rating

3

Overall EAPI gets a fundamental rating of 3 out of 10. We evaluated EAPI against 50 industry peers in the Pharmaceuticals industry. EAPI has a bad profitability rating. Also its financial health evaluation is rather negative. EAPI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EAPI has reported negative net income.
In the past year EAPI had a positive cash flow from operations.
EAPI had negative earnings in each of the past 5 years.
In the past 5 years EAPI always reported a positive cash flow from operatings.
EAPI.PA Yearly Net Income VS EBIT VS OCF VS FCFEAPI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of EAPI (-8.62%) is worse than 72.00% of its industry peers.
With a Return On Equity value of -13.04%, EAPI is not doing good in the industry: 72.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -8.62%
ROE -13.04%
ROIC N/A
ROA(3y)-7.13%
ROA(5y)-4.46%
ROE(3y)-11.69%
ROE(5y)-7.3%
ROIC(3y)N/A
ROIC(5y)N/A
EAPI.PA Yearly ROA, ROE, ROICEAPI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5 -10 -15 -20

1.3 Margins

EAPI has a Gross Margin of 13.71%. This is amonst the worse of the industry: EAPI underperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of EAPI has grown nicely.
The Profit Margin and Operating Margin are not available for EAPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.23%
GM growth 5Y10.12%
EAPI.PA Yearly Profit, Operating, Gross MarginsEAPI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10

More info and screens

3

2. Health

2.1 Basic Checks

EAPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
EAPI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EAPI has more shares outstanding
EAPI has a better debt/assets ratio than last year.
EAPI.PA Yearly Shares OutstandingEAPI.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EAPI.PA Yearly Total Debt VS Total AssetsEAPI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

EAPI has an Altman-Z score of 1.97. This is not the best score and indicates that EAPI is in the grey zone with still only limited risk for bankruptcy at the moment.
EAPI has a Altman-Z score of 1.97. This is in the lower half of the industry: EAPI underperforms 62.00% of its industry peers.
EAPI has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of EAPI (0.07) is better than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 1.97
ROIC/WACCN/A
WACC7.28%
EAPI.PA Yearly LT Debt VS Equity VS FCFEAPI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 2.53 indicates that EAPI has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.53, EAPI belongs to the best of the industry, outperforming 84.00% of the companies in the same industry.
EAPI has a Quick Ratio of 2.53. This is a bad value and indicates that EAPI is not financially healthy enough and could expect problems in meeting its short term obligations.
EAPI has a worse Quick ratio (0.80) than 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 0.8
EAPI.PA Yearly Current Assets VS Current LiabilitesEAPI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.83% over the past year.
The Revenue has decreased by -9.11% in the past year.
EAPI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.07% yearly.
EPS 1Y (TTM)56.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
Revenue 1Y (TTM)-9.11%
Revenue growth 3Y0.98%
Revenue growth 5Y0.07%
Sales Q2Q%-8.07%

3.2 Future

EAPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.85% yearly.
Based on estimates for the next years, EAPI will show a small growth in Revenue. The Revenue will grow by 0.68% on average per year.
EPS Next Y62.94%
EPS Next 2Y41.67%
EPS Next 3Y35.78%
EPS Next 5Y24.85%
Revenue Next Year-2.6%
Revenue Next 2Y-3.54%
Revenue Next 3Y-1.07%
Revenue Next 5Y0.68%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EAPI.PA Yearly Revenue VS EstimatesEAPI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EAPI.PA Yearly EPS VS EstimatesEAPI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 -0.4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EAPI. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 847.91, which means the current valuation is very expensive for EAPI.
70.00% of the companies in the same industry are cheaper than EAPI, based on the Price/Forward Earnings ratio.
EAPI is valuated expensively when we compare the Price/Forward Earnings ratio to 22.59, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 847.91
EAPI.PA Price Earnings VS Forward Price EarningsEAPI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600 800

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EAPI is valued cheaply inside the industry as 98.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.13
EAPI.PA Per share dataEAPI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EAPI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as EAPI's earnings are expected to grow with 35.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.67%
EPS Next 3Y35.78%

More info and screens

0

5. Dividend

5.1 Amount

EAPI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROAPI SASU

EPA:EAPI (9/10/2025, 5:28:17 PM)

2.88

-0.04 (-1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-29 2025-07-29
Earnings (Next)03-03 2026-03-03/amc
Inst Owners38.08%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap275.30M
Analysts46.15
Price Target2.86 (-0.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.58%
PT rev (3m)0.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)11.67%
EPS NY rev (3m)11.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.2%
Revenue NY rev (3m)-1.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 847.91
P/S 0.31
P/FCF N/A
P/OCF 3.94
P/B 0.29
P/tB 0.3
EV/EBITDA 4.13
EPS(TTM)-1.31
EYN/A
EPS(NY)0
Fwd EY0.12%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.73
OCFY25.39%
SpS9.24
BVpS9.97
TBVpS9.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE -13.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.71%
FCFM N/A
ROA(3y)-7.13%
ROA(5y)-4.46%
ROE(3y)-11.69%
ROE(5y)-7.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.23%
GM growth 5Y10.12%
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA 1.09
Cap/Depr 109.03%
Cap/Sales 9.57%
Interest Coverage N/A
Cash Conversion 117.28%
Profit Quality N/A
Current Ratio 2.53
Quick Ratio 0.8
Altman-Z 1.97
F-Score5
WACC7.28%
ROIC/WACCN/A
Cap/Depr(3y)120.54%
Cap/Depr(5y)120.13%
Cap/Sales(3y)13.95%
Cap/Sales(5y)12.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
EPS Next Y62.94%
EPS Next 2Y41.67%
EPS Next 3Y35.78%
EPS Next 5Y24.85%
Revenue 1Y (TTM)-9.11%
Revenue growth 3Y0.98%
Revenue growth 5Y0.07%
Sales Q2Q%-8.07%
Revenue Next Year-2.6%
Revenue Next 2Y-3.54%
Revenue Next 3Y-1.07%
Revenue Next 5Y0.68%
EBIT growth 1Y-516.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year254.35%
EBIT Next 3Y66.57%
EBIT Next 5Y39.11%
FCF growth 1Y90.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2696%
OCF growth 3Y19.68%
OCF growth 5Y28.63%